PNC‑27 is a 32‑amino‑acid peptide derived from p53’s HDM‑2 binding domain and is used in research to selectively lyse cancer cells. In the community the most common protocol is 200 µg per day, although doses reported range from 200 µg up to 15 mg, and users typically do not specify timing or cycling. The primary limitation is that the off‑label evidence base is thin, with most exploratory work lacking posted results, and no side effects have been consistently reported in the limited community data.
Data last updated
Measured on 2 of 6 axes
Evidence shape
PNC-27 currently lacks any human clinical evidence, as there are no published human trials or registered studies for this peptide. Research remains restricted to preclinical and mechanistic investigations, meaning there is no data to support its use or efficacy in human subjects. The absence of completed trials or human-grade literature indicates that the peptide has not progressed beyond early-stage laboratory exploration.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Symptom-relevant clinical or community evidence has not been captured for this peptide yet.
price offers can be sorted by column
How PNC-27 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Most community reports describe daily dosing, with doses ranging from 200 mcg to 15 mg; a smaller subset reports twice‑daily administration (e.g., 250 mcg).